ArticleTherapeutic advances in medical oncology2010
Predictive and prognostic molecular markers for cancer medicine.
Article in Therapeutic advances in medical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review.Journal for immunotherapy of cancer · 2023Pooled it
- Prognostic significance of lactate dehydrogenase and its impact on the outcomes of gastric cancer: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Copy number of 8q24.3 drives HSF1 expression and patient outcome in cancer: an individual patient data meta-analysis.Human genomics · 2019Pooled it
- Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany.Advances in therapy · 2016Pooled it
- From molecular pathogenesis to novel Therapeutic approaches - a review of recent advances in the treatment of peripheral T cell Lymphomas.Biomarker research · 2026Review
- CD30 Expression in Neoplastic Mast Cells and the Presence of CD30+, CD3+, and PAX-5+ Tumour-Infiltrating Lymphocytes as Prognostic Markers in Canine Cutaneous Mast Cell Tumours.Veterinary and comparative oncology · 2026Article
- A Melanoma-Specific Gene Network Analysis Identifies MZB1 as a Potential Tumor Promoter.The Journal of investigative dermatology · 2026Article
- The Neutrophil-to-Lymphocyte Ratio (NLR) as a Potential Predictor in Conization Outcomes for Cervical Cancer.Cancers · 2025Article
- Oxidative phosphorylation-related genes for prognosis and tumor microenvironment in breast cancer.Translational cancer research · 2025Article
- Extracellular RNA communication: A decade of NIH common fund support illuminates exRNA biology.Journal of extracellular vesicles · 2025Review
- Vasoactive Inotrope Score as a Predictor of Postoperative Complications in Cancer Surgery Patients-A Prospective Observational Study.Indian journal of surgical oncology · 2024Article
- Deregulation ofSaudi journal of biological sciences · 2024Article
- Hypermethylation of the Gene Body inBiomolecules · 2024Article
- Examining the Completeness of Breast Cancer Pathology Reports Registered in the Population-Based Cancer Registration System in Iran during 2016 to 2018.Medical journal of the Islamic Republic of Iran · 2024Article
- Pleural Uptake Patterns inJournal of clinical medicine · 2023Article
- Molecular pathology of colorectal cancer: The Saudi situation in perspective.Saudi medical journal · 2023Review
- Predicting cervical lymph node metastasis in OSCC based on computed tomography imaging genomics.Cancer medicine · 2023Article
- Chemo Markers as Biomarkers in Septic Shock: A Comprehensive Review of Their Utility and Clinical Applications.Cureus · 2023Review
- Review
- A Current Review of Machine Learning and Deep Learning Models in Oral Cancer Diagnosis: Recent Technologies, Open Challenges, and Future Research Directions.Diagnostics (Basel, Switzerland) · 2023Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last 10 years there has been an explosion of information about the molecular biology of cancer. A challenge in oncology is to translate this information into advances in patient care. While there are well-formed routes for translating new molecular information into drug therapy, the routes for translating new information into sensitive and specific diagnostic, prognostic and predictive tests are still being developed. Similarly, the science of using tumor molecular profiles to select clinical trial participants or to optimize therapy for individual patients is still in its infancy. This review will summarize the current technologies for predicting treatment response and prognosis in cancer medicine, and outline what the future may hold. It will also highlight the potential importance of methods that can integrate molecular, histopathological and clinical information into a synergistic understanding of tumor progression. While these possibilities are without doubt exciting, significant challenges remain if we are to implement them with a strong evidence base in a widely available and cost-effective manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.